Daiichi Sankyo (OTCMKTS:DSNKY) Stock Price Crosses Below 50 Day Moving Average – What’s Next?

Daiichi Sankyo Co., Ltd. – Sponsored ADR (OTCMKTS:DSNKY – Get Free Report) crossed below its fifty day moving average during trading on Tuesday. The stock has a fifty day moving average of $17.80 and traded as low as $17.5940. Daiichi Sankyo shares last traded at $17.68, with a volume of 74,227 shares.

Analyst Upgrades and Downgrades

A number of research firms have issued reports on DSNKY. Jefferies Financial Group cut Daiichi Sankyo from a “buy” rating to a “hold” rating in a report on Thursday, July 30th. Zacks Research lowered Daiichi Sankyo from a “hold” rating to a “strong sell” rating in a report on Tuesday, October 20th. One research analyst has rated the stock with a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, Daiichi Sankyo presently has an average rating of “Reduce”.

Get Our Latest Analysis on Daiichi Sankyo

Daiichi Sankyo Price Performance

The firm has a market cap of $33.35 billion, a price-to-earnings ratio of 18.27, a PEG ratio of 2.00 and a beta of -0.10. The company’s fifty day moving average is $17.78 and its 200 day moving average is $17.55. The company has a quick ratio of 1.96, a current ratio of 2.92 and a debt-to-equity ratio of 0.29.

Daiichi Sankyo (OTCMKTS:DSNKY – Get Free Report) last issued its quarterly earnings results on Friday, October 30th. The company reported $0.29 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.21 by $0.08. Daiichi Sankyo had a net margin of 12.13% and a return on equity of 16.31%. The firm had revenue of $3.77 billion for the quarter, compared to analyst estimates of $3.58 billion. On average, equities research analysts predict that Daiichi Sankyo Co., Ltd. – Sponsored ADR will post 0.87 EPS for the current year.

Daiichi Sankyo Company Profile

(Get Free Report)

Daiichi Sankyo is a Japan-based pharmaceutical company that researches, develops, manufactures and markets medicines. Formed in 2005 through the merger of Sankyo and Daiichi Pharmaceutical, the company has a particular focus on oncology and also develops treatments in areas such as cardiovascular disease and other serious conditions. Its portfolio includes Enhertu (trastuzumab deruxtecan), an antibody-drug conjugate developed in collaboration with AstraZeneca, as well as medicines such as Lixiana (edoxaban) and Vanflyta (quizartinib).

Further Reading

Receive News & Ratings for Daiichi Sankyo Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Daiichi Sankyo and related companies with MarketBeat.com's FREE daily email newsletter.